DexCom (NASDAQ:DXCM) Price Target Raised to $94.00

DexCom (NASDAQ:DXCM) had its target price boosted by Wells Fargo & Company from $90.00 to $94.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have an overweight rating on the medical device company’s stock.

DXCM has been the topic of a number of other research reports. Royal Bank of Canada cut their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Raymond James reduced their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research note on Friday, October 25th. Leerink Partners lowered their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Canaccord Genuity Group raised their price target on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $98.00.

DexCom Price Performance

DXCM stock opened at $77.19 on Wednesday. The stock has a market cap of $30.15 billion, a PE ratio of 46.34, a P/E/G ratio of 2.46 and a beta of 1.12. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a 50-day moving average price of $73.58 and a 200 day moving average price of $84.99. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of DXCM. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom during the second quarter valued at $25,000. Sachetta LLC lifted its holdings in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares in the last quarter. Riverview Trust Co grew its position in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the period. DT Investment Partners LLC increased its stake in shares of DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares in the last quarter. Finally, RPg Family Wealth Advisory LLC purchased a new stake in shares of DexCom during the third quarter worth about $57,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.